M923 (adalimumab biosimilar) / J&J  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
M923 (adalimumab biosimilar) / J&J
NCT02722044: Usability of an AI for M923 in Subjects With Moderate to Severe RA

Completed
3
33
US
M923, Adalimumab, Autoinjector
Momenta Pharmaceuticals, Inc.
Rheumatoid Arthritis
02/17
02/17
NCT02581345 / 2015-001751-76: Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

Checkmark P3 trial complete for chronic plaque-type psoriasis
Jul 2017 - Jul 2017: P3 trial complete for chronic plaque-type psoriasis
Checkmark For the treatment of psoriasis
Nov 2016 - Nov 2016: For the treatment of psoriasis
Completed
3
572
Canada, US, Europe, RoW
M923, Adalimumab, Humira
Momenta Pharmaceuticals, Inc.
Chronic Plaque Psoriasis, Psoriasis
04/17
04/17

Download Options